Logo

CAPR

Capricor Therapeutics, Inc.

CAPR

Capricor Therapeutics, Inc. • NASDAQ
$5.35 ▲ 3.08% (+0.16)
Market Cap $244.59 M
52w High $20.75
52w Low $4.30
Dividend Yield 0%
P/E -3.06
Volume 1.77M
Outstanding Shares 45.72M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $5.925M ▲ $-24.571M ▲ 0% $-0.54 ▲ $-24.076M ▲
Q2-2025 $0 $5.672M ▼ $-25.911M ▼ 0% $-0.57 ▼ $-27.233M ▼
Q1-2025 $0 ▼ $6.067M ▲ $-24.392M ▼ 0% ▲ $-0.53 ▼ $-24.577M ▼
Q4-2024 $11.131M ▲ $4.273M ▲ $-7.117M ▲ -63.938% ▲ $-0.16 ▲ $-7.322M ▲
Q3-2024 $2.262M $3.464M $-12.557M -555.204% $-0.38 $-12.649M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $98.566M ▼ $126.438M ▼ $42.571M ▲ $83.867M ▼
Q2-2025 $122.801M ▼ $133.569M ▼ $28.592M ▲ $104.977M ▼
Q1-2025 $144.777M ▼ $153.766M ▼ $26.121M ▲ $127.645M ▼
Q4-2024 $151.516M ▲ $170.481M ▲ $25.019M ▲ $145.462M ▲
Q3-2024 $85.029M $92.952M $24.687M $68.265M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $0 ▲ $0 ▲ $0 ▼ $0 ▼ $0 ▲ $0 ▲
Q2-2025 $-25.911M ▼ $-20.122M ▼ $14.549M ▼ $19.58K ▼ $-5.553M ▼ $-21.572M ▼
Q1-2025 $-24.392M ▼ $-6.434M ▲ $23.891M ▲ $50.354K ▼ $17.508M ▲ $-7.574M ▲
Q4-2024 $-7.117M ▲ $-14.796M ▼ $-123.382M ▼ $81.088M ▲ $-57.09M ▼ $-15.531M ▼
Q3-2024 $-12.557M $-11.642M $2.005M $67.327M $57.689M $-11.702M

Five-Year Company Overview

Income Statement

Income Statement Capricor looks like a typical clinical‑stage biotech on the income side: almost no product revenue and recurring operating losses. The small amount of revenue likely comes from collaborations or grants rather than commercial sales. Expenses tied to R&D and overhead have kept the company in the red for several years, and per‑share losses have been consistent. In short, the business is still in the investment phase, spending heavily to develop its pipeline without yet having a meaningful product income stream to offset those costs.

Balance Sheet

Balance Sheet The balance sheet is small but relatively clean. Assets have grown recently, suggesting the company has raised capital or secured additional funding, while still carrying no financial debt, which reduces interest burden and refinancing risk. Equity has improved from a very thin base, but overall resources remain limited, meaning the company does not have a large cushion if trials are delayed or costs rise. The history of reverse stock splits hints at past dilution and pressure to maintain listing standards.

Cash Flow

Cash Flow Cash flow reflects a development‑stage biotech: money consistently flows out of the business to fund operations, with no offsetting inflows from profitable products. Operating and free cash flow are both negative and have been for years, while capital spending is minimal. This pattern means Capricor remains reliant on external funding—through equity offerings, partnerships, or grants—to keep its programs moving forward, and timing of clinical or regulatory milestones will be important for future financing.

Competitive Edge

Competitive Edge Capricor’s competitive edge comes from its focus on cell and exosome therapies for Duchenne muscular dystrophy and other high‑need areas. Its lead therapy is designed to work regardless of a patient’s specific genetic mutation and puts special emphasis on heart complications, which differentiates it from many gene therapies and mutation‑specific drugs. The StealthX exosome platform adds a second pillar with potential applications in targeted drug delivery and vaccines. Partnerships with organizations like Nippon Shinyaku, Lonza, and U.S. government agencies add credibility and potential reach. On the other hand, Capricor is small and competes against larger, well‑funded players in both DMD and exosome technologies, and it has recently faced regulatory pushback on its lead program, which weighs on its competitive standing until further data can de‑risk the story.

Innovation and R&D

Innovation and R&D Innovation is the core of Capricor’s value. The company is advancing a novel cell therapy for Duchenne that aims to reduce inflammation and scarring rather than replace the missing gene, potentially allowing use across a broad patient population and in combination with other treatments. At the same time, the StealthX exosome platform targets next‑generation delivery of genetic and protein‑based medicines, including a government‑funded COVID‑19 vaccine project that could validate the platform in humans. A growing patent portfolio and academic partnerships help protect these technologies. However, the company is still in the clinical‑stage, with key trials ongoing and a recent FDA rejection that requires stronger evidence, so scientific, regulatory, and execution risks remain high.

Summary

Capricor is an early‑stage biotech with promising but unproven science and a fragile financial profile. The company has minimal revenue and ongoing losses, but no debt and a recently strengthened—though still modest—asset base. It is burning cash to progress its pipeline and remains dependent on future financings and partnerships. Strategically, Capricor’s differentiation lies in a mutation‑independent Duchenne therapy that targets heart disease and a versatile exosome platform with potential across multiple disease areas, backed by notable partners and intellectual property. The main opportunities are successful pivotal data, regulatory progress, and platform validation; the main risks are clinical failure, further regulatory hurdles, funding needs, competitive pressure from larger players, and share dilution. Overall, this is a high‑risk, high‑uncertainty profile typical of small clinical‑stage biotechnology companies whose fortunes hinge on a few upcoming trial and regulatory milestones.

NEWS

November 10, 2025 · 10:16 AM UTC

Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm

Read more

November 5, 2025 · 7:56 AM UTC

Caprock Announces Option and RSU Grant

Read more

November 3, 2025 · 9:15 AM UTC

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Read more

October 31, 2025 · 9:15 AM UTC

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Read more

October 28, 2025 · 2:20 PM UTC

Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm

Read more